Evaluation of the Ezibreath in patients with chronic obstructive pulmonary disease

慢性阻塞性肺疾病（COPD）是全球第四大死因，预计到2020年将成为第三大死因。COPD是加拿大主要慢性病中住院率最高的疾病。最近的研究为COPD和睡眠障碍之间的关联提供了强有力的证据。事实上，睡眠相关的投诉频率排名第三，仅次于COPD患者的呼吸急促和疲劳。活动记录仪是一种用于在患者自己家中舒适地监测睡眠模式的非侵入性技术，并且是复杂且昂贵的基于实验室的测试（例如多导睡眠图（PSG））的有吸引力的替代方案。 Agartee开发了一种专为COPD患者设计的创新活动记录仪。该设备被称为“Ezibreath”，可以测量许多重要的变量，这些变量可以远程发送给护理提供者，以帮助监测和管理COPD患者。例如，Ezibreath测量身体活动水平，心率，吸入器使用和睡眠等变量。在公司发展的这个阶段，Agartee必须在进行验证研究之前优化其算法的准确性。Agartee的首要任务是优化他们的睡眠算法。因此，他们将与不列颠哥伦比亚省大学的助理教授Jordan Guenette博士合作， 实验室睡眠测试该研究将在12名临床稳定的中重度COPD患者中同时比较Ezibreath和PSG。然后，他们将使用来自黄金标准PSG的信息来改进他们的算法，以优化Ezibreath的准确性。

Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide and is projected to be the third leading cause of death by 2020. COPD accounts for the highest rate of hospital admissions among major chronic illnesses in Canada. Recent studies have provided strong evidence for an association between COPD and sleep disturbance. In fact, sleep-related complaints rank third in frequency, behind shortness of breath and fatigue in patients with COPD. Actigraphy is a non-invasive technique for monitoring sleep patterns in the comfort of a patient's own home and is an attractive alternative to complex and expensive laboratory based tests such as polysomnography (PSG). Agartee has developed an innovative actigraph specifically designed for patients with COPD. The device, known as the "Ezibreath", can measure many important variables that can be sent remotely to care providers to assist in the monitoring and management of patients with COPD. For example, the Ezibreath measures physical activity levels, heart rate, inhaler use, and sleep, among other variables. At this stage in the company's development, Agartee must optimize the accuracy of their algorithms before they can conduct validation studies. Agartee's first priority is to optimize their sleep algorithms. Accordingly, they will work with Dr. Jordan Guenette, an Assistant Professor at the University of British Columbia to test the Ezibreath during formal laboratory sleep testing. The study will simultaneously compare the Ezibreath to PSG in 12 clinically stable patients with moderate-to-severe COPD. They will then use the information from the gold standard PSG to refine their algorithms to optimize the accuracy of the Ezibreath.